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Sir,
An investigation of anti-BK virus antibodies among immuno-
suppressed patients with BK-related nephropathy was beyond the
scope of the EPIC-Oxford cohort study (Newton et al, 2005), but
has been carried out by others. Hariharan et al (2005) found that
mean BK virus-specific IgG levels in patients with early onset and
stabilizing BK virus nephropathy were significantly lower than
those seen after the disease had resolved. Mean plasma BK virus
load declined over the same period. Chen et al (2006) observed
that low anti-BK virus antibodies were associated with a low viral
load and strong cytotoxic T lymphocyte (CTL) response and that
viral persistence among transplant recipients was associated with
high antibody titres and a poor CTL response. However, for results
to be truly comparable to those reported by us, antibody titres
among such patients would need to be assessed using the same
assay, preferably performed at the same time and under the same
laboratory conditions.
We agree that our prospective investigation does not exclude the
possibility of a ‘hit-and-run’ role for BK virus in the aetiology of
any of the cancers studied. However, there is no example of such a
mechanism in the aetiology of cancer. Indeed among patients with
cancers that are known to be related to prevalent infections, such
as Kaposi’s sarcoma (human herpesvirus 8), cancer of the uterine
cervix (human papillomaviruses) or endemic African Burkitt
lymphoma (Epstein Barr virus), elevated titres of antibodies
against the relevant viral antigens have been found both in
prospective and in retrospective studies (for examples see
references: de-The ´ et al, 1978; Sitas et al, 1999; Newton et al,
2004; Newton et al, in press).
However, we can also report some additional evidence against a
role for BK virus in the aetiology of prostate cancer. Using
immunohistochemistry, 10 consecutive prostate cancer tissue
sections were incubated with antibodies to the SV40 T antigen.
This antibody cross reacts with the BK virus large T-antigen
expressed on infected cells and is used routinely to identify
polyoma virus infection among transplant recipients with haemor-
rhagic cystitis or nephropathy (Mann and Carroll, 1984). Presence
of viral protein is associated with characteristic nuclear staining.
None of the samples tested were positive for SV40T antigen,
suggesting that BK viral proteins are not expressed on tumour
cells. These results are in accord with those of a previous study,
which also reported negative results for bladder cancer (Shah et al,
1978). Lack of BK virus protein does not exclude the possibility
that viral DNA is present, although previous studies designed to
identify BK virus genomes in normal prostate tissue and in
prostate cancer cells have produced inconsistent results and are
difficult to interpret (Zambrano et al, 2002; Das et al, 2004).
In relation to bladder cancer, on the basis of only nine cases, we
found no evidence that anti-BK virus antibodies were associated
with the tumour. Only one published study has reported finding
SV40 T antigen present in tumour tissue (but not in adjacent
normal tissue), but this was an unusual case in an immuno-
suppressed transplant recipient (Geetha et al, 2002). Studies of
bladder cancer in immunocompetent people have not found SV40
T antigen (Shah et al, 1978). BK virus DNA has been identified in
papillary urothelial bladder carcinoma in one study (Monini et al,
1995).
A common morphological sign of active polyoma virus infection
is the presence in urine of bladder epithelial cells with typical
intranuclear viral inclusions. These ‘decoy cells’ are so named
because they mimic the nuclear enlargement and atypia of
urothelial carcinomas and can easily be mistaken for malignant
cells. Weinreb draws attention to his recent report (Weinreb et al,
2006) in which decoy cells were identified in urine cytology
specimens (using the Papinicolaou method) of apparently
immunocompetent people who subsequently developed bladder
cancer. While interesting, the interpretation of this finding is
uncertain. In order to exclude a diagnosis of cancer and confirm
BK virus infection, the presence of decoy cells on urine cytology
should be followed by staining for SV40 T antigen. No such
confirmatory tests were reported by Weinreb and co-workers.
Although his study was prospective, no detail is provided about the
time between urine cytology and diagnosis of bladder cancer and
we suggest that the decoy cells could in fact have been malignant
cells, despite the authors’ assertion to the contrary. Urine samples
were not available in the EPIC-Oxford cohort.
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